New Biologics Facility J.POD, Toulouse

Biologics are a highly effective therapeutic option with broad applicability across many indications. However, the traditional fed-batch manufacturing presents significant challenges, especially when upscaling from clinical to commercial supply. With a modular continuous manufacturing setup, the J.POD® technology allows for highly intensified cGMP manufacturing of biologics at flexibly scalable quantities, thus reducing both scale-up risks and manufacturing costs significantly. Evotec Biologics’ second J.POD® facility marks an important milestone on their path to making biologics globally available.

Value add

• Linesight’s experience and expertise, while working closely with Just Evotec Biologics, were a pivotal part in the establishment and administration of the processes and procedures for the project’s cost and change management practices. 
• Linesight assisted Just Evotec Biologics in developing a suitable contracting strategy that allowed them to appoint quality contracts to execute the project. Linesight continues to support through constant Open Book Reviews of the contractors’ costs to ensure transparency and fairness for both Just Evotec Biologics and their contractors.
• Linesight provides Just Evotec Biologics with key resources to ensure tight budget controls and project delivery within timeframes provided.
• Linesight’s global reach allowed Just Evotec Biologics access to experienced Life Sciences professionals to work on this project.